Evidence map›Paper›PMID 25962159›Full record

ArticlePloS one2015

An ShRNA Based Genetic Screen Identified Sesn2 as a Potential Tumor Suppressor in Lung Cancer via Suppression of Akt-mTOR-p70S6K Signaling.

Hui Xu, Huiying Sun, Haiyuan Zhang, Jiawei Liu, Fangfang Fan, Yilan Li, Xuelian Ning, Yue Sun, Shaochun Dai, Baogang Liu and 3 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 35 citations in OpenAlex.

  1. Article
  2. Review
  3. T-Cell Intracellular Antigen 1-Like Protein in Physiology and Pathology.International journal of molecular sciences · 2022
    Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. T-cell intracellular antigens in health and disease.Cell cycle (Georgetown, Tex.) · 2015
    Review
  18. Article
  19. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Hui XuThe Laboratory of Medical Genetics, Harbin Medical University, Harbin, China.
Huiying SunThe Laboratory of Medical Genetics, Harbin Medical University, Harbin, China.
Haiyuan ZhangThe Laboratory of Medical Genetics, Harbin Medical University, Harbin, China.
Jiawei LiuThe Laboratory of Medical Genetics, Harbin Medical University, Harbin, China.
Fangfang FanThe Laboratory of Medical Genetics, Harbin Medical University, Harbin, China.
Yilan LiThe Laboratory of Medical Genetics, Harbin Medical University, Harbin, China.
Xuelian NingThe Laboratory of Medical Genetics, Harbin Medical University, Harbin, China.
Yue SunThe Laboratory of Medical Genetics, Harbin Medical University, Harbin, China.
Shaochun DaiThe Tumor Hospital, Harbin Medical University, Harbin, China.
Baogang LiuThe Tumor Hospital, Harbin Medical University, Harbin, China.
Min GaoThe Fourth Affiliated Hospital, Harbin Medical University, Harbin, China.
Songbin FuThe Laboratory of Medical Genetics, Harbin Medical University, Harbin, China.
Chunshui ZhouThe Laboratory of Medical Genetics, Harbin Medical University, Harbin, China.
Harbin Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLung cancer is emerging rapidly as the leading death cause in Chinese cancer patients. The causal factors for Chinese lung cancer development remain largely unclear. Here we employed an shRNA library-based loss-of-function screen in a genome-wide and unbiased manner to interrogate potential tumor suppressor candidates in the immortalized human lung epithelial cell line BEAS-2B. METHODS/

resultsSoft agar assays were conducted for screening BEAS-2B cells infected with the retroviral shRNA library with the acquired feature of anchorage-independent growth, large (>0.5mm in diameter) and well-separated colonies were isolated for proliferation. PCRs were performed to amplify the integrated shRNA fragment from individual genomic DNA extracted from each colony, and each PCR product is submitted for DNA sequencing to reveal the integrated shRNA and its target gene. A total of 6 candidate transformation suppressors including INPP4B, Sesn2, TIAR, ACRC, Nup210, LMTK3 were identified. We validated Sesn2 as the candidate of lung cancer tumor suppressor. Knockdown of Sesn2 by an shRNA targeting 3' UTR of Sesn2 transcript potently stimulated the proliferation and malignant transformation of lung bronchial epithelial cell BEAS-2B via activation of Akt-mTOR-p70S6K signaling, whereas ectopic expression of Sens2 re-suppressed the malignant transformation elicited by the Sesn2 shRNA. Moreover, knockdown of Sesn2 in BEAS-2B cells promoted the BEAS-2B cell-transplanted xenograft tumor growth in nude mice. Lastly, DNA sequencing indicated mutations of Sesn2 gene are rare, the protein levels of Sesn2 of 77 Chinese lung cancer patients varies greatly compared to their adjacent normal tissues, and the low expression level of Sesn2 associates with the poor survival in these examined patients by Kaplan Meier analysis.

conclusionsOur shRNA-based screen has demonstrated Sesn2 is a potential tumor suppressor in lung epithelial cells. The expression level of Sesn2 may serve as a prognostic marker for Chinese lung cancer patients in the clinic.

Indexed as

Signal TransductionAnimalsCell Line, TumorCell MovementCell Transformation, NeoplasticDisease Models, AnimalEpithelial CellsGene Expression Regulation, NeoplasticGene SilencingGenes, Tumor SuppressorHeterograftsHumansLung NeoplasmsMutationNuclear ProteinsProto-Oncogene Proteins c-aktNuclear ProteinsProto-Oncogene Proteins c-aktRibosomal Protein S6 Kinases, 70-kDaRNA, Small InterferingSESN2 protein, humanSestrinsTOR Serine-Threonine Kinases

Identifiers

PMID25962159
PMCPMC4427398
OpenAlexW254553107

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.